大麻二醇在发育性和性脑病变中的实际有效性和安全性

相关实验视频

Updated: Jan 12, 2026

05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.9K

Marco Perulli^1,2, Maddalena Bianchetti^1,2, Gloria Pantalone³

¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Epilepsia open

|October 30, 2025

概括

大麻 (CBD) 有效地减少严重患者的发作,包括非标签用途. 这项现实研究显示了良好的耐受性和潜在的非发作益处,支持更广泛的CBD应用.

科学领域:

神经学神经学
药理学药理学是指药理学的学科.
发病学 (Epileptology) 是一个专业的学科.

背景情况:

高净化大麻 (CBD) 已被批准用于特定的,如德拉维特综合征 (DS),伦诺克斯-加斯托综合征 (LGS) 和结核性硬化综合体 (TSC).
在更广泛的发育性和性脑病变 (DEE) 中,包括非标签性指示中,CBD的疗效和安全性需要进一步研究.

研究的目的:

评估CBD作为DEE多样化的患者队列中的辅助疗法的实际使用,有效性和安全性.
探索治疗反应的预测因素,并确定与DEE中CBD使用相关的非结局.

主要方法:

一项回顾性研究评估了107名DEE患者在2020年至2024年期间至少3个月用CBD治疗.
收集的数据包括发作频率,耐受性,治疗持续时间和非发作结果. 疗效被定义为≥50%或≥75%的发作减少.

主要成果:

69%的患者实现了≥50%的发作减少,21%的患者在20个月的中位随访期实现了≥75%的发作减少.
与DS相比,在LGS,TSC和其他DEE患者中观察到更高的疗效和保留率. 遗传或未知的病因与更好的结果相关.
非的改善包括提高警觉性 (56%),改善睡眠 (25%),提高运动性能 (14%). 33.6%的患者出现了不良事件,大多数是轻微的,9%的患者因副作用而停止治疗.

结论:

现实数据证实了CBD在DEE患者的有效性和良好的耐受性,包括非标签性适应症.
这些发现支持扩大CBD的批准适用范围,并强调需要进行前性研究,评估和发育结果.

关键词:

在这里,我们可以看到CBD CBD CBD CBD.迪伊·迪伊是什么意思德拉维特综合征是什么?德拉维特综合征是什么列诺克斯加斯塔特综合症列诺克斯加斯塔特综合症现实世界的世界.

相关概念视频

01:24

Epilepsy and Seizures: Overview

1.1K

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

1.1K

01:20

Antiepileptic Drugs: Potassium Channel Activators

620

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

620

01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

804

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

804

01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.2K

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...

1.2K

01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

185

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

185

01:28

Preclinical Development: Overview

5.8K

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...